KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Share-based Compensation (2016 - 2025)

Pfizer (PFE) has disclosed Share-based Compensation for 17 consecutive years, with $225.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 27.12% to $225.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $799.0 million, a 8.89% decrease, with the full-year FY2025 number at $799.0 million, down 8.89% from a year prior.
  • Share-based Compensation was $225.0 million for Q4 2025 at Pfizer, up from $201.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $686.0 million in Q4 2021 to a low of $86.0 million in Q2 2022.
  • A 5-year average of $231.2 million and a median of $202.0 million in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 201.75% in 2021, then tumbled 70.28% in 2023.
  • Pfizer's Share-based Compensation stood at $686.0 million in 2021, then decreased by 25.95% to $508.0 million in 2022, then tumbled by 76.18% to $121.0 million in 2023, then surged by 46.28% to $177.0 million in 2024, then increased by 27.12% to $225.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Share-based Compensation are $225.0 million (Q4 2025), $201.0 million (Q3 2025), and $203.0 million (Q2 2025).